Numerion Labs

numerionlabs.ai →

-20%

est. 2Y upside i

HealthcareSeries D+

Artificial intelligence for drug discovery.

Rank

#2755

Sector

Drug Discovery

Est. Liquidity

~4Y

Data Quality

Data: Low

Numerion Labs offers strong technology but a severely capital-heavy balance sheet with $246M in preferred stock against a $122.5M valuation.

Last updated: July 19, 2026

Bull (10%)+169%

Partnerships or acquisition at $600M net common $354M; 189% pre-dilution, 169% after 20% dilution.

Base (50%)+6%

Organic growth leads to exit at $400M; common $154M, 25.7% pre-dilution, 5.7% after dilution.

Bear (40%)-100%

Exit below $246M preference; common recovers nothing, -100%.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

0%

Total funding $246M exceeds current valuation $122.5M, resulting in a 2x preference overhang; common shares only receive proceeds above $246M at exit.

Dilution Risk

high

Company has raised $246M but latest round was only $19.8M; likely to raise additional capital within 24 months, diluting current equity by ~20%.

Secondary Liquidity

none

No secondary market data available; no liquidity before exit.

Questions to Ask at the Interview

Strategic questions based on Numerion Labs's data — designed to show you've done your homework.

  • 1

    “How does Numerion plan to generate revenue from its platform given the lack of disclosed revenue?”

  • 2

    “What is the company's runway and when do you anticipate needing another funding round?”

  • 3

    “Given the preference stack, how do you align equity incentives for early employees?”

Community

Valuation Sentiment

Our model estimates -20% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.